Lack of CD 117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature

Diagnostic Pathology

Volumn 1, Issue 1, 2006, Pages

  Mireskandari, Masoud ^a   Shafaii, Ali Fakhr ^a   Kayser, Gian ^b   Kayser, Klaus ^c  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF FREIBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248149331     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-1-7     Document Type: Article

References (51)

1. Akin C, Schwartz LB, Kitoh T, Obayoshi H, Worbec AS: Soluble stem cell factor receptor (CD 117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis, relationship to disease severity and bone marrow pathology. Blood 2000, 96:1267-73.
2. Araki K, Ishii G, Yokose T, Nagai K, Funai K, Kodama K, Nishiwaki Y, Ochiai A: Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2003, 40:173-80.
3. Ashman KL: The biology of stem cell factor and its receptor c-kit. Int J Biol 1999, 31:1037-51.
4. Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andre T, Mareel M, Master J, Gespach C.: The kit thyrosine kinase inhibitor STI57I forcolorectal cancer therapy. Cancer Res 2002, 62:4879-83.
5. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23:2162-71.
6. Bellone G, Silvestri S, Artusio E, Tibaudi D, Turletti A, Geuna M, Giachino C, Valente G, Emanuelli G, Rodech U: Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-β1. J Cell Physiol 1997, 172:1 -11.
7. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ: Effects of imatinibe mesylate on neuroblastoma tumorgenesis and vascular endothelial growth factor expression. J Notl Cancer Inst 2004, 96:46-55.
8. Blanke CD, Coia LR, Schwarz RE, Bonin SR: Gastric cancer management. In Cancer management: a multidisciplinary approach 9th edition. Edited by: Richard Pazdur, William J Hoskins, Lawrence R Coia, Lawrence D Wagman. CMP Healthcare Media; 2005:279.
9. Camirand A, Pollak M: Co-targeting IGF-1R and c-kit: synergistic inhibition proliferation and induction of apoptosis, in H 209 small lung cancer cells. Br J Cancer 2004, 90:1825-9.
10. Canonico B, Felici C, Papa S: CD 117. J Biol Regul Homeost Agents 2001, 15:90-4.
11. Chen XL, Su BS, Sun RQ, Zhang J, Wang YL: Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma. World J Gastroenterol 2005, 11:1228-1231.
12. de Jong FA, Verweij J: Role of imatinib mesylate (Gleevec/-Glivec) in gastrointestinal stromal tumors. Expert Rev Anticancer Ther 2003, 3:757-66.
13. Feng HL, Sawndlow JI, Sporks AE, Sandra A: Deacreased level of the c-kit receptor is associated with increased apoptosis in subfertile human testes. Fertility and Sterility 1999, 71:85-9.
14. Forones NM, Carvalho AP, Giannotti-Filho O, Lourenco LG, Oshima CT: Cell proliferation and apoptosis in gastric cancer and intestinal metaplasia. Arq Gastroenterl 2005, 42:30-4.
15. Fricke E, Keller G, Becker I, Rosivatz E, Schott C, Plaschke S, Rudelius M, Hermannstadter C, Busch R, Hofler H, Becker KF, Luber B: Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma. Int J Cancer 2003, 10:60-5.
16. Gonzalez I, Andreu EJ, Panizo A, Inoges S, Fontalba A, Fernandez-Luna JL, Gaboli M, Sierrasesumaga L, Martin-Algarra 5, Pardo J, Prosper F, de Alava E: Imatinib inhibits proliferation of Ewing sarcoma tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004, 10:751-61.
17. Hamel W, Westphal M: The road less traveled: c-kit and stem cell factor. J Neurooncol 1997, 35:327-33.18.
18. Hassan S, Kinoshita Y, Kawaname C, Hishik O, Fanaska C: Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci 1998, 35:327-33.
19. Higashiyama M, Monden T, Ogawa M, Matsuura N, Murotani M, Kawasaki Y, Tomita N, Murata A, Shimano T, Mori T: Immunohistochemical study on pancreatic secretory trypsin inhibitor (PSTI) in gastric carcinomas. Am J Clin Pathol 1990, 93:8-13.
20. Hines SJ, Organ C, Kornstein MJ, Krystal JW: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 1995, 6:769-79.
21. Hornick JL, Fletcher CDM: Immunohistochemical staining for c-kit (CD 117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002, 117:188-93.
22. Immunohistochemistry Literature Database Query System [http://www.immunoquery.com/]
23. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B: Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005, 65:264-76.
24. Jiang X, Gurel O, Mendiaz EA, Stearns GW, Clogston CL, Lu HS, Osslund TD, Syed RS, Langley KE, Hendrickson WA: Structure of active core of human stem cell factor and analysis of binding to its receptor kit. EMBO J 2000, 19:3 192-203.
25. Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC: kit mutations are common in testicular seminomas. Am J Pathol 2004, 164:305-13.
26. Kim R, Emi M, Matsuura K, Tanabe K: Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma. Gan To Kagaku Ryoho 2005, 32:1540-5.
27. Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T: Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004, 103:3644-54.
28. Lahm H, Amstad P, Yilmaz A, Borbenyi Z, Wyniger J, Fischer JR, Suardet L, Givel JC, Odartchenko N: Interlukin 4 down-regulates expression of c-kit and stem cell factor in human colorectal carcinoma cells. Cell Growth Differ 1995, 6:11 11 -8.
29. Lauren F: The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt to histoclinical classification. Acta Pathol Microbiol Scand 1995, 64:31-40.
30. Levesque JP, Hendy J, Winkler IG, Takamatsu Y, Simmons PJ: Granulocyte colony stimulating factor induces the release in the bone marrow of proteases that cleave c-kit receptor (CD 117) from the surface of hematopoietic progenitor cells. Exp Hemotol 2003,m 31:109-17.
31. Liu HF, Liu WW, Wang GA, Teng XC: Effect of Helicobacter pylori infection on Bax protein expression in patients with gastric precancerous lesions. World J Gastroenterol 2005, 11:5899-5901.
32. Liu W, Guo QL, You QD, Zhao L, Gu HY, Yuan ST: Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J Gastroenterol 2005, 11:3655-3659.
33. Matsui J, Wakabayashi T, Asoda M, Yoshimatsuk O: Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells, J Biol Chem 2004, 279:186-7.
34. Miettinen M: New challenges in the identification of gastrointestinal stromal tumors and other possible KIT-deriven tumors. Am J Clin Pathol 2002, 117:183-185.
35. Nakamura Y, Tajima F, Ishiga K, Yamazaki H, Oshimura M, Shiota G, Murawaki Y: Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. Exp Hematol 2004, 32:390-6.
36. Nakatani T, Marui T, Yamamoto T, Hitora T, Akisue T, Kawamoto T, Nagira K, Fujita l, Matsumoto K, Yoshiya S, Kurosaka M: Expression of stem cell factor and c-kit in human malignant fibrous histiocytoma cell line (TNMYI). Anticancer Res 23:2329-33.
37. Nishida K, Tsukamoto T, Uchida K, Takahashi T, Takahashi T, Ueda R: Introduction of the c-kit gene leads to growth suppression of breast cancer cell line, MCF-7. Anticancer Res 1996, 16:3397-402.
38. Ramadori G, Fuzesi L, Grabbe E, Pieler T, Armbrust T: Successful treatment of hepatocellular carcinoma with thyrosine kinase inhibitor imatinib mesylate in a patient with liver cirrhosis. Anticancer Drugs 2004, 15:405-9.
39. Raspollini MR, Paglierani M, Taddei GL, Villanucci A, Amunni G, Taddei A: The protooncogene c-kit is expressed in leiomyosarcoma of the uterus. Gynecol Oncol 2003, 93:718.
40. Reed J, Ouban A, Schickor FK, Muraca P, Yeatman T, Coppola D: Immunohistochemical staining for c-kit (CD117) is a rare event in colorectal carcinoma. Comment in J Clin Oncol 2003, 21:3885-6. discussion 3887-9
41. Reedy MV, Johnson RL, Erickson CA: The expression patterns of c-kit and SI in chicken embryos suggest unexpected role for these agents in somite and limb development. Gene Expression Patterns 2003, 3:53-58.
42. Romagnoli S, Graziani D, Bramerio M, Gambacorta M, Colombo P, Roncalli M, Coggi G, Bosari S: Imunohistochemical profile and c-kit mutations in gastrointestinal stromal tumors. Pothol Res Pract 2005, 201:71-81.
43. Rosai J, Ed: Ackerman's Surgical Pathology 9th edition. St. Louis: Mosby; 2004.
44. Sandberg AA, Bridge JA: Updates on cytogenetics and molecular genetics of bone and soft tissue tumors, gastrointestinal stromal tumors. Cancer Genet Cytogenet 2002, 135:1 -22.
45. Spiekermann K, Faber F, Voswinckel R, Hiddemann W: The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol 2002, 30:767-73.
46. Surgical Oncology Net [http://www.surgical-oncology.net]
47. Wang J, Chi DS, Kalin GB, Sosinski C, Miller LE, Burja I, Thomas E: Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dig Sci 2002, 47:107-13.
48. Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, Garcia-Echeverria C, Krystal GW: The insulin-like growth factor I (IGF-1) receptor kinase inhibitor NVP-ADW742 in combination with ST1571 decline spectrum of dependence of small cell lung cancer on IGF-stem cell factor signaling. Mol Cancer Ther 2004, 3:527-35.
49. Watanabe H, Tokuyama H, Ohta H, Satomura Y, Okai T, Ooi A, Mai M, Sawabu N: Expression of placental alkaline phosphatase in gastric and colorectal cancers. An immunohistochemical study using the prepared monoclonal antibody. Cancer 1990, 66(12):2575-82.
50. Xia HH, Talley NJ: Apoptosis in gastric epithelium induced by helicobacter pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol 2001, 96:16-26.
51. Yamamoto T, Nakatani T, Marui T, Akisue T, Fujita I, Matsumoto K, Hitora T, Kawamoto T, Nagira K, Kurosaka M: Expression of stem cell factor and lack of c-kit expression in malignant fibrous histiocytoma of soft tissue. Anticancer Res 2003, 23:4305-8.